Paxlovid

Search documents
Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts
Seeking Alpha· 2025-10-06 12:00
Pfizer Inc. (NYSE: PFE ) gave us strong 2Q25 figures. We saw double-digit revenue growth, margin expansion, and rising earnings. Mainly driven by key products like Comirnaty, Paxlovid, and Vyndaqel. However, the big news this quarter is, of course, theI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific fo ...
Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts (NYSE:PFE)
Seeking Alpha· 2025-10-06 12:00
Pfizer Inc. (NYSE: PFE ) gave us strong 2Q25 figures. We saw double-digit revenue growth, margin expansion, and rising earnings. Mainly driven by key products like Comirnaty, Paxlovid, and Vyndaqel. However, the big news this quarter is, of course, theI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific fo ...
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
ZACKS· 2025-10-03 15:01
Core Insights - Pfizer has entered a significant agreement with the Trump administration to reduce drug prices and enhance U.S. innovation and manufacturing [1][10] - The deal includes price reductions for certain drugs to match costs in comparable developed countries and substantial discounts through a new purchasing platform [2][4] - Pfizer will invest an additional $70 billion in U.S. manufacturing in exchange for a three-year exemption from tariffs on pharmaceutical imports [3][10] Drug Pricing and Market Impact - Pfizer will implement price cuts of up to 85%, averaging 50%, on key treatments [2] - The stock price of Pfizer increased nearly 14% following the announcement, alleviating major concerns in the pharmaceutical industry regarding tariffs and pricing proposals [4][10] - Other major drugmakers also saw stock gains, indicating potential for similar agreements in the industry [4] Oncology and Product Pipeline - Pfizer is a leading player in oncology, with revenues from oncology drugs growing 9% in the first half of 2025 [6] - The acquisition of Seagen has strengthened Pfizer's oncology portfolio, with expectations of eight or more blockbuster oncology medicines by 2030 [7][10] - New and acquired products contributed $4.7 billion in revenues in the first half of 2025, reflecting a 15% operational increase year-over-year [9][10] Financial Performance and Projections - Pfizer anticipates a revenue compound annual growth rate (CAGR) of approximately 6% from 2025 to 2030, with the Seagen acquisition expected to add over $10 billion in risk-adjusted revenues by 2030 [11][10] - The company expects to face challenges from declining COVID product sales, with revenues dropping from $56.7 billion in 2022 to around $11 billion in 2024 [12] - Pfizer is preparing for a significant impact from loss of exclusivity (LOE) on key products between 2026 and 2030 [13] Cost Management and Future Outlook - Pfizer aims to achieve savings of $7.7 billion by the end of 2027 through cost cuts and restructuring [22] - Despite anticipated revenue challenges, Pfizer expects earnings per share (EPS) growth and maintains a dividend yield of around 7% [22][24] - The company has announced plans to acquire Metsera, re-entering the obesity drug market after previously halting development on another weight-loss drug [23][24] Valuation and Investment Considerations - Pfizer's stock is trading at a price/earnings ratio of 8.70, significantly lower than the industry average of 15.93, indicating attractive valuation [18] - The Zacks Consensus Estimate for earnings has increased for 2025 and 2026, reflecting positive sentiment [20] - Investors are encouraged to consider Pfizer for long-term investment due to its cheap valuation, high dividend yield, and growth prospects [24]
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9.5% -- Which Are No-Brainer Buys in October
The Motley Fool· 2025-10-01 07:51
Three supercharged income stocks have the catalysts necessary to pad the pocketbooks of patient investors.For more than a century, the stock market has reigned supreme as the most-decorated wealth creator. No asset class has come close to matching the average annual return of stocks -- and with thousands of publicly traded companies to choose from, there's likely one or more securities that can help you reach your investment goals.But among the countless ways to grow your wealth, buying and holding high-qua ...
Pfizer agrees to lower drug prices, invest $70 bn in U.S. under Trump administration deal
BusinessLine· 2025-10-01 03:25
Drugmaker Pfizer has agreed to lower drug costs under a deal struck with the Trump administration, President Donald Trump said Tuesday, as he promised similar deals will be struck with other drugmakers facing a threat of tariffs.The announcement, which Trump made with Pfizer CEO Albert Bourla at the White House, came as the Republican president has for months sought to lower drug costs. It also came as Washington faced a federal government shutdown at midnight amid a standoff between Democrats and Republic ...
Pfizer strikes $70B deal with Trump to cut Medicaid drug prices, expand U.S. manufacturing under tariff threat
Fortune· 2025-09-30 20:20
Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.Trump made the announcement at the White House alongside Pfizer CEO Albert Bourla just hours ahead of a possible government shutdown in a partisan standoff over health care and spending.Pfizer Inc., one of the largest U.S. drugmakers, produces the COVID-19 vaccine Comirnaty ...
Trump jokes about getting Covid and needing Paxlovid after RFK Jr. sneezes
NBC News· 2025-09-30 18:15
People weren't taking it. I would imagine they just they couldn't take God bless you, Bobby. I hope I didn't catch CO just there.Mr. . President, sir, he's got me a fax immediately. ...
Why Pfizer's Post-COVID Future Looks Brighter Than Ever
Yahoo Finance· 2025-09-28 17:28
Key Points Sales of Pfizer's COVID-19 products have collapsed. Thanks to heavy investment fueled by COVID-related revenue, Pfizer has a big pipeline of new potential blockbuster drugs. Cancer treatments Pfizer acquired from Seagen in 2023 are driving growth. 10 stocks we like better than Pfizer › It's been a rough few years to be a Pfizer (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirna ...
Where Will Pfizer Be in 5 Years?
The Motley Fool· 2025-09-24 07:55
Core Viewpoint - Pfizer is transitioning towards a new era of growth after experiencing significant revenue from coronavirus-related products, but is now facing challenges due to declining sales and upcoming patent expirations [1][2]. Revenue and Financial Performance - Pfizer achieved over $100 billion in annual revenue in 2022, primarily driven by its coronavirus products, but is now realigning costs to match future revenue opportunities, aiming for over $7 billion in cost savings by 2027 [4]. - The company has seen its stock decline nearly 30% over the past five years due to concerns over patent expirations for key products [2][5]. Product Pipeline and Growth Strategy - Pfizer is preparing for the loss of exclusivity on four major drugs, including Eliquis and Ibrance, which could lead to revenue declines [5]. - The company has launched a significant number of new products, predicting that these could generate $20 billion in revenue by 2030, with recent launches contributing $4.7 billion [7][9]. - Pfizer's acquisition of Seagen is expected to enhance its oncology portfolio, with projections of $10 billion in revenue from Seagen's drugs by 2030 [8]. Research and Development Focus - Pfizer is reinvesting savings from its cost realignment into R&D to support ongoing programs and maintain a robust pipeline [8]. - The company aims to achieve over $80 billion in non-coronavirus product revenues by 2030, up from approximately $63 billion last year [9]. Future Outlook - Despite facing hurdles from patent expirations, Pfizer's strategic initiatives are expected to yield new growth opportunities, with the potential for new blockbuster drugs to drive revenue gains in the coming years [10].
Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies
Yahoo Finance· 2025-09-23 23:10
Group 1: Company Overview - Pfizer Inc. is recognized as a global biopharmaceutical leader, making significant advancements in vaccines and oncology, which solidifies its position in the pharmaceutical sector [1] - The company is targeting $4.5 billion in cost savings by the end of 2025, with plans to reinvest these savings into research and development for innovative therapies [4] Group 2: Vaccine Developments - In September 2025, Pfizer and BioNTech reported positive Phase 3 data for the LP.8.1-adapted COMIRNATY 2025-2026 COVID-19 vaccine, showing at least a four-fold increase in neutralizing antibodies among adults aged 65 and older, as well as high-risk adults aged 18-64 [2] - The updated vaccine formulation has demonstrated robust protection against emerging SARS-CoV-2 sublineages and has been submitted to the FDA for ongoing authorization for vulnerable populations during upcoming flu seasons [2] Group 3: Oncology Pipeline - Pfizer is advancing its oncology pipeline with successful combination therapies, such as the PADCEV plus KEYTRUDA regimen, which improved survival rates in bladder cancer patients [3] - The XTANDI with leuprolide combination has significantly benefited high-risk metastatic prostate cancer patients, showcasing the company's commitment to expanding critical cancer treatments [3] Group 4: Financial Performance - Pfizer's financial performance remains strong, bolstered by sales of its COVID-19 vaccine and Paxlovid, along with growth in its oncology and hematology segments [4] - Licensing agreements, such as the recent deal with China's 3SBio, are aimed at expanding access to experimental oncology therapies targeting multiple tumor types [4]